Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus versus placebo emollient for localized scleroderma
NL-OMON31329Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in morphea comparing Tacrolimus 0.1% with Placebo emollient (2 arms). Primary endpoints: Clinical and histological response after 3 months and Adverse reactions. Planned start Oct 2007; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
morphea
Beyond the preview
Go deeper on NL-OMON31329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31329.